Jennifer Driver, MD
Family Medicine · New Orleans, LANPI 1588076608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 63.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $289 and has fallen 65.7% since, to $99 in 2025. That places this record below the midpoint for family medicine clinicians in LA, where the typical reported total is $645.
Across 40 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$478
- Lilly USA, LLC$107
- Teva Pharmaceuticals USA, Inc.$43
- Pfizer$36
- Mayne Pharma Commercial LLC$22
- Boehringer Ingelheim$19
- plus $50 from 3 others
Across 2 payments — averaging $1552.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Food & beverage$755100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $478 |
| Lilly USA, LLC | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Pfizer | 2 | $36 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Bayer | 1 | $15 |
How this compares
$755 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 100 | $138,921 |
| OzempicSemaglutide | 71 | $74,237 |
| JardianceEmpagliflozin | 68 | $73,668 |
| EliquisApixaban | 45 | $38,878 |
| ProliaDenosumab | 21 | $36,436 |
| Nurtec OdtRimegepant Sulfate | 11 | $19,569 |
| WegovySemaglutide | 13 | $17,951 |
| SynthroidLevothyroxine Sodium | 52 | $6,008 |
| Atorvastatin Calcium | 335 | $3,352 |
| Levothyroxine Sodium | 287 | $2,319 |
| Estradiol | 32 | $2,123 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $1,768 |
| Valsartan | 49 | $1,575 |
| Losartan Potassium | 167 | $1,346 |
| Gabapentin | 128 | $1,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $107 | $138,921100 claims |
| Boehringer IngelheimJardiance | $19 | $73,66868 claims |
| PfizerEliquis, Nurtec Odt | $36 | $58,44756 claims |
| AbbVieSynthroid | $478 | $6,00852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Orleans
- Ibrahim ZeinatyNew Orleans$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
- Leonard TreanorHammond$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.